Sermorelin is the first 29 amino acids of growth hormone releasing hormone, the signal your hypothalamus sends to tell the pituitary to release growth hormone. The natural version is 44 amino acids long, but researchers found the first 29 do the whole job, so that is what sermorelin is.
The appeal is that it asks your body to make its own growth hormone rather than supplying it from outside. Injected growth hormone overrides your natural control system and keeps levels flat and high. Sermorelin nudges the pituitary and then lets your normal feedback loop, including the off switch called somatostatin, do its work. Levels rise in pulses, which is how the body does it naturally.
That makes it one of the most widely prescribed peptides at hormone and wellness clinics, usually taken at bedtime to line up with the body's own overnight growth hormone pulse.
It used to be an approved drug in the United States, sold as Geref. It was pulled from the market in 2008 for commercial reasons rather than safety concerns, a distinction the FDA has documented. Today it is available through compounding pharmacies.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
No reviews yet. Be the first.
Sermorelin sits in an odd evidence position. Its mechanism is very well established, and it was approved as a medicine, but the trial data for how people actually use it today is thin.
The pathway is not in doubt. It binds the GHRH receptor on the pituitary and triggers growth hormone release, which is why the approved use was as a diagnostic test of pituitary function and a treatment for growth hormone deficiency in children. Those uses are supported by proper studies.
What is missing is randomized trial data on healthy middle aged adults using it for body composition, sleep, and general wellbeing, which is nearly all of its current use. Most of the confidence there is borrowed from tesamorelin, a related GHRH analogue with solid human trial data for reducing visceral fat, plus the reasonable argument that both act on the same receptor through the same pathway.
Borrowed evidence is still weaker than direct evidence. Raising growth hormone through a natural pathway is a sound idea with a long safety history, but the specific claims made in anti-aging marketing have not been tested in the population being marketed to.